Building on a robust 6-year relationship, Fujifilm's customers who rely on ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) now have access to the latest technologies from Volpara's Breast Health Platform.
FREMONT, CA: FUJIFILM Medical Systems U.S.A., a leading provider of diagnostic imaging and medical informatics solutions, and Volpara Solutions, a purpose-driven software company, have expanded their partnership to provide mammography facilities with breast imaging solutions designed to optimize image quality, streamline workflow, and precisely examine a patient's breast density.
Building on a robust 6-year relationship, Fujifilm's customers who rely on ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) now have access to the latest technologies from Volpara's Breast Health Platform. VolparaLive! helps decrease patient recalls due to poor image quality by giving mammographers instant feedback on positioning and compression—which the FDA attributes as the reason behind most image deficiencies—for adjustment before the patient leaves the room. Volpara Enterprise offers a comprehensive analysis of quality on every mammogram and tomosynthesis image taken at the facility to identify improvement chances.
"Consistent mammography quality and accuracy are critical to ensuring that we are able to provide women the best possible breast health care. We are excited to work with Fujifilm and Volpara to implement a system-wide quality program across our entire network, including the University of Utah's Huntsman Cancer Institute and our Community Breast Care Centers," said Laurie Fajardo, MD, Professor of Radiology at the University of Utah, School of Medicine and the Department of Radiology and Imaging Sciences.
Dense breast tissues are associated with a high risk of developing breast cancer. Volpara 's Enterprise consists of a module that uses patented x-ray physics, AI, and machine learning to produce precise volumetric measurements of breast composition. It offers a repeatable, persistent, and objective method of calculating breast density.
"Providing an accurate and consistent assessment of breast density is vital to identifying women at high risk of developing breast cancer and determining their screening path," said Katherine Singson, CEO, Volpara Solutions. "Volpara's AI-based breast health platform, coupled with a leading modality solution like the Fujifilm ASPIRE Cristalle, offers a powerful combination to identify this destructive disease in its early stages."
Today, more than 9,000 global customers use Fujifilm's Digital Mammography Solutions, and more than 2,000 U.S. facilities rely on Volpara technology and services. Together, both the firms are leading a mission to deliver a suite of women's health products that contribute to early diagnosis and treatment of breast cancer.
